A more active role for gynecologists in the prevention of postmenopausal osteoporosis

Gynecological Endocrinology

Volumn 24, Issue 6, 2008, Pages 293-294

  Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTRADIOL; HEPARIN; IBANDRONIC ACID; RISEDRONIC ACID; STRONTIUM RANELATE; THYROXINE;

BONE DENSITY; CALCIUM INTAKE; DIETARY INTAKE; EDITORIAL; FEMALE; HIP FRACTURE; HUMAN; LIFESTYLE; LUMBAR SPINE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WEIGHT BEARING;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GYNECOLOGY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 46349103789     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802243403     Document Type: Editorial

References (10)

1. Gill JM, Hoffman MK. Prevention and treatment of osteoporosis in primary care offices. Womens Health (Larchmt) 2003;12:473-480.
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578.
3. Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin 2004;20:525-531.
4. Simon JA, Wehren LE, Ascott-Evans BH, Omizo MK, Silfen SL, Lombardi A. Skeletal consequences of hormone therapy discontinuance: a systematic review. Obstet Gynecol Surv 2006;61:115-124.
5. Kanis JA, Johnell O, Oden A, De Laet C, de Terlizzi F. Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography. Osteoporos Int 2005;16:1065-1070.
6. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006;13:340-367.
7. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042-1048.
8. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 2007;57:81-84.
9. van de Weijer PH, Matsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007;56:231-248.
10. Eviö S, Tiitinen A, Laitinen K, Ylikorkala O, Välimäki MJ. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004;89:626-631.